Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 16, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 17, 2026 — +20.1% at the close.
Predicted vs. what happened
What happened
Reached its target in 78 days.
The thesis — published February 16, 2026
Arrowhead is a short-term, news-driven biotech that can move a lot. Recent positives: an early US launch of REDEMPLO showing initial prescriptions and a $1.33 billion financing that eases near-term funding pressure. Together these shift the story toward how well the launch performs, not just cash worries. Because the stock has been volatile, treat any position as a smaller, staged trade and watch launch metrics closely-poor launch news could cause big down moves.
Primary drivers
- REDEMPLO early script growth could surprise on the upside
- Large financing eases near-term funding pressure
- Biotech news can quickly move the stock both ways, so stage buys
- Adding this helps healthcare exposure if other sectors wobble
How it played out
ARWR: target reached in 78 days
Lyra published ARWR at $63.82 on February 16, 2026, with expected growth of 22%. The thesis pointed to REDEMPLO early prescription growth, a $1.33 billion financing that eased near-term funding pressure, biotech news volatility, and added healthcare exposure if other sectors wobbled.
Inside the window, ARWR rose to a peak of $82 on May 14, 2026. That was above the $77.86 target, and the target was reached in 78 days. The peak gain was 28.5%. By May 17, 2026, it ended at $76.67. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.